The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Katherine Wolkoff for The New York Times Supported by By Lisa Miller Lisa Miller interviewed more than two dozen people about the ... to seriously consider taking Zepbound, one of the new ...

Weight-loss drugs such as Ozempic have been a breakthrough because they eliminate the need to cut back or compensate by ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

We provided a digital sleep lounge that offered people ... for the use of Zepbound, a GLP-1 in patients with obesity and moderate-to-severe sleep apnea with a reduced calorie diet and physical ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Even so, GLP-1 agonists like Wegovy, Zepbound, and Saxenda (made with the same active ingredient as Victoza) have proven more successful in people with obesity ... been able to control your blood ...

Lee Herring, 31, weighed 351 pounds and wore a size 5XL at his heaviest, when he would gorge on chocolate, sweets, cream buns ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

When we want to know about ancestors and prehistory, we’d do better to consult an archaeologist than someone trying to sell a diet The expert ... claiming that people used to live without ...